Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of umedaptanib pegol in children with achondroplasia
jRCT2061260037Phase 3Recruiting
- Sponsor
- Ribomic Inc.
- Start
- Jul 2026
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of umedaptanib pegol in achondroplasia (ACH), sponsored by Ribomic Inc. Started Jul 2026; status: recruiting.
02
Drugs
umedaptanib pegol
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on jRCT2061260037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061260037.